Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin aspart 30 vs NovoMix 30 plus metformin in type 2 diabetes
CTR20192588Phase 3Active
- Sponsor
- Beijing SL Pharmaceutical
- Start
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of insulin aspart in type 2 diabetes mellitus (T2DM), sponsored by Beijing SL Pharmaceutical. Started Dec 2019; status: active.
02
Drugs
insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20192588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192588.